Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Breast-Cancer-2022-1000x250

Satellite Symposia Resources from OncologyPRO sponsors

Find here all the resources from Industry Satellite Symposia published by our industry partners.

Treatment Sequencing in HER2-Positive Metastatic Breast Cancer: From Guidelines to Clinical Practice

10-Treatment-Sequencing-in-HER2-Positive-Metastatic-Breast-Cancer-SEAGEN-Thumb

Watch the webcasts

  • Introduction
  • Patient case study: how does treatment sequencing vary in local clinical practice across Europe for HER2-positive MBC?
  • Patient case study: how does local clinical practice vary for patients with brain metastases?
  • Which local factors influence treatment sequencing for HER2-positive MBC?
  • Consistency of approach: how can we personalise and adapt treatment sequencing for patients with HER2-positive MBC?
  • Q&A
  • Summary and session close

Broadening Horizons in HER2- Advanced Breast Cancer

09-Broadening-Horizons-in-HER2-Advanced-Breast-Cancer-PFIZER-ONCOLOGY-Thumb

Watch the webcasts

  • Welcome and introductions
  • Expanding perspectives: Progress in treatment choice in HER2- aBC
  • Managing individual needs: Real-world evidence in HER2- aBC
  • Q&A, discussion and close

Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice

17-Aiming-to-Minimize-the-Risk-of-Recurrence-in-Early-Breast-Cancer-LILLY-Thumb

Watch the webcasts

  • Welcome and Introduction
  • Predicting Risk of Recurrence in HR-positive, HER2-negative Early Breast Cancer: A Focus on Clinicopathological Factors
  • Tools to Guide Risk Assessment and Adjuvant Treatment Decisions in HR-positive, HER2-negative Early Breast Cancer: A Focus on Best Practices
  • Impact of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Recent Evidence
  • Optimizing the Use of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Patient Management
  • Questions and Take-Home Learnings

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.